IP Library Granted Patent US 10,709,721
Granted Patent B2
US 10,709,721 · App. 15/554,369 · Granted Jul 14, 2020

Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,721
App. No.
15/554,369
Granted
Jul 14, 2020
Kind
B2
Abstract

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in a particular ratio, for use in preventing and/or treating gastrointestinal infections and/or gastrointestinal inflammations in an infant or a young child.

Claims (17)

1. A method for treating gastrointestinal inflammations in an infant or a young child in need thereof, the method comprising administering to the infant or the young child in need thereof a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide,

wherein a ratio of the at least one fucosylated oligosaccharide: the at least one N-acetylated oligosaccharide is from 1:2 to 6.7:1, the at least one fucosylated oligosaccharide is in a total amount of 0.5-2 g/L of the nutritional composition and/or 0.34-1.4 g/100 g of the nutritional composition on a dry weight basis, and the at least one N-acetylated oligosaccharide is selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), para-lacto-N-neohexaose (para-LNnH), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose, para-lacto-N-neohexaose, lacto-N-octaose, lacto-N-neooctaose, iso-lacto-N-octaose, para- lacto-N-octaose, lacto-N-decaose and combinations thereof, and wherein the nutritional composition does not have 3′ sialyllactose (3-SL) and does not have 6′ sialyllactose (6-SL).

2. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3 ′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and any combination thereof.

3. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide comprises a 2′ fucosyl-epitope.

4. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is 2′-fucosyllactose (2′FL).

5. The method according to claim 1 , wherein the at least one N-acetylated oligosaccharide is selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), para-lacto-N-neohexaose (para-LNnH) and combinations thereof.

6. The method according to claim 1 , wherein the nutritional composition comprises (i) 2′ fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT) or (ii) an oligosaccharide mixture consisting of 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT).

7. The method according to claim 1 , wherein the ratio of the at least one fucosylated oligosaccharide: the at least one N-acetylated oligosaccharide is from 1:1.5 to 4:1.

8. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is in a total amount selected from the group consisting of 0.75-1.65 g/L of the nutritional composition, 0.52-1.15 g/100 g of the nutritional composition on a dry weight basis, 0.8-1.5 g/L of the composition, 0.55-1.05 g/100 g of the nutritional composition on a dry weight basis, 0.85-1.3 g/L of the nutritional composition, 0.59-0.9 g/100 g of the nutritional composition on a dry weight basis, 1-1.25 g/L of the nutritional composition, and 0.69-0.87 g/100 g of the nutritional composition on a dry weight basis.

9. The method according to claim 1 , wherein the at least one N-acetylated oligosaccharide is in a total amount selected from the group consisting of 0.3-1 g/L of the nutritional composition, 0.2-0.7 g/100 g of the nutritional composition on a dry weight basis, 0.45-0.85 g/L of the nutritional composition, 0.31-0.59 g/100 g of the nutritional composition on a dry weight basis, 0.5-0.8 g/L of the nutritional composition, 0.35-0.56 g/100 g of the nutritional composition on a dry weight basis, 0.5-0.75 g/L of the nutritional composition, 0.35-0.52 g/100 g of the nutritional composition on a dry weight basis, 0.5-0.7 g/L of the nutritional composition, and 0.35-0.49 g/100 g of the nutritional composition on a dry weight basis.

10. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is in a total amount of 1-1.25 g/L of the nutritional composition and/or 0.69-0.87 g/100 g of the nutritional composition on a dry weight basis; and the at least one N-acetylated oligosaccharide is in a total amount of 0.5-0.7 g/L of the nutritional composition and/or 0.35-0.49 g/100 g of the nutritional composition on a dry weight basis.

11. The method according to claim 1 , wherein the nutritional composition comprises at least another oligosaccharide and/or a fiber and/or a precursor.

12. The method according to claim 1 , wherein the nutritional composition further comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of the nutritional composition on a dry weight basis.

13. The method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.

14. The method according to claim 1 , wherein the gastrointestinal inflammations are inflammations of the lower gastrointestinal tract.

15. The method according to claim 1 , wherein the gastrointestinal inflammations have an origin selected from the group consisting of a bacterial origin, a viral origin, a fungal origin, a parasitic origin and an environmental origin.

16. The method according to claim 1 , wherein the gastrointestinal inflammations are selected from the group consisting of enteritis, gastroenteritis, infectious diarrhea, enterocolitis, necrotizing enterocolitis (NEC), oesophagitis and combinations thereof.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: SPRENGER, NORBERT; BRASSART, DOMINIQUE; EGLI, DELPHINE
To: NESTEC S.A.
Reel/Frame 044317/0897 →